Esperion Therapeutics Inc (NASDAQ: ESPR) is -21.36% lower on its value in year-to-date trading and has touched a low of $1.58 and a high of $3.94 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ESPR stock was last observed hovering at around $1.82 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $1.73, the stock is -6.44% and -17.00% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.87 million and changing -4.95% at the moment leaves the stock -20.74% off its SMA200. ESPR registered -34.22% loss for a year compared to 6-month gain of 1.17%.
The stock witnessed a -17.62% loss in the last 1 month and extending the period to 3 months gives it a -28.22%, and is -7.49% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.25% over the week and 5.63% over the month.
Esperion Therapeutics Inc (ESPR) has around 240 employees, a market worth around $340.87M and $295.45M in sales. Profit margin for the company is -29.37%. Distance from 52-week low is 9.49% and -56.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-58.53%).
with sales reaching $61.58M over the same period.The EPS is expected to grow by 84.40% this year, but quarterly earnings will post 179.14% year-over-year. Quarterly sales are estimated to grow 90.96% in year-over-year returns.
Esperion Therapeutics Inc (ESPR) Top Institutional Holders
The shares outstanding are 195.44M, and float is at 195.08M with Short Float at 16.02%.
The top institutional shareholder in the company is WASATCH ADVISORS LP with over 16.86 million shares valued at $37.44 million. The investor’s holdings represent 8.9319% of the ESPR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 13.98 million shares valued at $31.04 million to account for 8.2617 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 10.82 million shares representing 6.3907% and valued at over $24.01 million, while BELLEVUE GROUP AG holds 5.2672 of the shares totaling 9.94 million with a market value of $22.08 million.
Esperion Therapeutics Inc (ESPR) Insider Activity
The most recent transaction is an insider sale by Warren Eric, the company’s Chief Commercial Officer. SEC filings show that Warren Eric sold 239 shares of the company’s common stock on Feb 19 ’25 at a price of $1.87 per share for a total of $446.0. Following the sale, the insider now owns 0.16 million shares.
Esperion Therapeutics Inc disclosed in a document filed with the SEC on Feb 19 ’25 that Halladay Benjamin (Chief Financial Officer) sold a total of 11 shares of the company’s common stock. The trade occurred on Feb 19 ’25 and was made at $1.86 per share for $20.0. Following the transaction, the insider now directly holds 0.24 million shares of the ESPR stock.
Still, SEC filings show that on Feb 19 ’25, Warren Eric (Officer) Proposed Sale 239 shares at an average price of $1.87 for $446.0. The insider now directly holds shares of Esperion Therapeutics Inc (ESPR).
